# Cyclization Reaction of $N$-Aroyl- $N^{\prime}$-(2-hydroxyethyl)ureas: One-Pot Synthesis of 1-Aroyl-2-imidazolidinones 

Tack Hyeon Kim,* Dong Ryun Oh, and Jac Young So<br>Faculty of Applied Chemistry, Chomam Vational Unversitu. Swangu 500-757, Sorea<br>Recened May 16, 2000

Cyclic ureas have recently gained much interest as pharmaceuticals for human immunodeficiency virus (HIV) protcase inhibitors ${ }^{1}$ and $5-\mathrm{HT}_{3}$ receptor antagonists. ${ }^{2}$ In addition. 5 - membered cyelic ureas. 2-imidazolidinones. are also used as useful chiral ausiliaries ${ }^{3}$ in highly diastercoselective alkylation. aldol. and Diels-Alder reactions. Several synthetic routes to 2 -imidazolidinones include the cyclization reaction of 1.2 -diamine with phosgene. ${ }^{+}$phosgene derivatives. ${ }^{2}$ dialkyl carbonate. ${ }^{5}$ carbonyl sulfide. ${ }^{6}$ and carbonyl selenide ${ }^{7}$ and these methods cause the polymerization as a side reaction. ${ }^{\text {B }}$ Recently. we reported a synthetic method for 2-imidazolidinones from 1.2 -aminoalcohol by onc-pot reaction of $N$-(2-hydroxyethyl)ureas with TsCl and $t-\mathrm{BuOK}$ without using phosgene gas (Scheme 1). ${ }^{9} \mathrm{~N}$-(2-Hydroxychyl)ureas 1 were derived from 1.2-aminoalcohols and phenyl isocyanate. In this paper we examine another nucleophile such as aroylureas for this one-pot reaction. Aroylureas 3 can conceivably proceed through mild nucleophilic attack upon the tosylate intermediate in the presence of $t$ - BuOK either by the nitrogen to give the 2 -imidazolidinone 4 or by the onygen atom to provide 2 -oxazoline 5 . However, we expected that the increased acidity of iminodicarboyl group relative to phenylureas might favor the formation of 2-imidazolidinone.


Scheme 1



3



4
Scheme 2

Aroylureas 3 were readily prepared from the reaction of 1.2-aminoalcohols with benzoyl isocyanate or 2.4 -dichlorobenzoyl isocyanate. ${ }^{\text {le }}$ The next step was to achiese ring closure by activating the primary hydroxy group wia a transfer activation ${ }^{\text {sill }}$ using TsCl and $t$ - BuOK (Scheme 2). The cyclization of a variety of substrates $3 \mathrm{a}-3 \mathrm{f}$ was examined (Table 1). Contrary to phenylurcas 1. aroy lureas $\mathbf{3 b}$ and 3 e prepared from $N$-unsubstituted aminoalcohols gave the unexpected mixture of both N - and O-alkylated products in low yiclds. In comparison to $\mathbf{3 b}$. however. aroylurea 3 e afforded more $N$-alkylated product te (entries $b$ and $c$ ). because an increase in the $\mathrm{N}-\mathrm{H}$ acidity by changing the substitution pattern in the bezene ring was anticipated to increase the $N$ - to O-alkylation ratio. With 3a. 3c. and 3d prepared from $N$-substituted aminoalcohols. as expected. $N$ cyclization to 2 -imidazolidinones was mainly observed with trace amount of the O-cyclized products regardless of the substitution pattern in the bezene ring. Aroylurea 3f prepared from 2 -aminoethanol did not undergo cyclization reaction upon this condition. The remarkable $N$-cyclization selectivity in aroylureas with $\alpha-N$-alkyl group may occur through a buttressing effect of $\alpha-N$-alkyl group in the cyclization. ${ }^{12}$ The present 2 -imidazolidinones 4 can be deacylated and alkylated to provide $N . N^{\prime}$-disubstituted cyclic ureas, overcoming the general difficulties associated with the synthesis of tetrasubstituted ureas. ${ }^{1.3}$

## Experimental Section

General. ${ }^{\text {J }} \mathrm{H}$ NMR and ${ }^{13} \mathrm{C}$ NMR spectra were recorded

Table 1. Preparations of Aroylureas 3 and 1-Aroyl-2-imidazolidinoncs 4

| Fintry | $\mathrm{R}^{1}$ | $\mathrm{R}^{2}$ | $\mathrm{R}^{3}$ | $\mathrm{R}^{+}$ | $\begin{gathered} \text { yield (\%) } \\ \text { of } 3^{x} \end{gathered}$ | mp <br> ol 3 | $\begin{gathered} \text { yichl (\%) } \\ \text { of } 4 \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| a | F.t | H | H | Ph | 85 | 158-160 | 82 |
| b | H | Me | Me | Ph | $95^{-6}$ | 122-124 | $11(33 / 67)$ |
| c | F.t | H | H | $2,4-\mathrm{Cl}_{2} \mathrm{Ph}$ | 92 | 124-126 | 94 |
| d | Me | H | H | $2,4-\mathrm{Cl}_{2} \mathrm{Ph}$ | 8.3 | 153-155 | 81 |
| e | H | Me | Me | $2,4-\mathrm{Cl}_{2} \mathrm{Ph}$ | 84 | 20.205 | $48(70 / 30)^{r}$ |
| f | H | H | H | $2,4-\mathrm{Cl}_{2} \mathrm{Ph}$ | 8.3 | 126-128 | ne ${ }^{\prime \prime}$ |

[^0]using $300 \mathrm{MH} \neq$ and $75 \mathrm{MH} z$ NMR spectrometer: chemical shifts are reported in ppm using TMS as internal standard. Melting points were determined on a capillary apparatus and uncorrected. Analytical TLC was performed on 0.25 mm precoated silica gel plates. Flash column chromatography was carricd out with 230 - 400 mesh silica gel.

General Procedure for Preparation of A roylureas 3.
A solution of aroyl isocyanate ( 2.4 mmol ) in tetrahydrofuran ( 5 mL ) was added over 10 min to a solution of 2 aminocthanol ( 2.4 mmol ) in tetrahy drofuran ( 15 mL ) cooled in an ice bath. The reaction mixture was stirred for 30 min and evaporated. The crude products except 3b were purified by the recrystallization in n-hexane/small amount of acctone or cthanol.

1-Benzoyl-3-ethyl-3-(2-hydroxyethyl)urea (3a). 'H NMR $\left(300 \mathrm{MH} \nsim . \mathrm{CDCl}_{3}\right) \delta 7.86-7.83(\mathrm{~m} .2 \mathrm{H}) .7 .50-7.45(\mathrm{~m} . \mathrm{lH})$. $7.40-7.35(\mathrm{~m} .2 \mathrm{H}) .3 .90(1.2 \mathrm{H} . J=4.3 \mathrm{H} \%) .3 .47(\mathrm{t} .2 \mathrm{H} . J=$ $4.3 \mathrm{H} \delta) .3 .33(\mathrm{q} .2 \mathrm{H} . J=7.2 \mathrm{H} \%) .1 .16(1.3 \mathrm{H} . J=7.2 \mathrm{H} \%)$.

1-Benzoyl-3-[(2-hydroxy-1,1-dimethyl)ethylJurea (3b). $R_{f}=0.3$ (ethyl acetate/n-hexane $1: 1$ ): ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \%$. $\mathrm{CDCl}_{3}$ ) $\delta 9.04$ (bs. 2H). 7.91-7.89 (m. 2H). 7.64-7.58 (m. $1 \mathrm{H}) .7 .54-7.48(\mathrm{~m} .2 \mathrm{H}) .3 .88(\mathrm{~s} .1 \mathrm{H}) .3 .68(\mathrm{~d} .2 \mathrm{H} . J=6.1$ $\mathrm{H} \%$ ). 1.40 (s. 6 H ): ${ }^{13} \mathrm{C}$ NMR ( $75 \mathrm{MH} \not . . \mathrm{CDCl}_{3}$ ) $\delta 168.7$. 154.5. 133.2. 132.3. 128.9. 127.9. 70.4. 55.6. 24.5.

1-(2,+-Dichlorobenzoyl)-3-ethyl-3-(2-hydroxyethyl)urea (3c). ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \approx . \mathrm{CDCl}_{3}$ ) $\delta 7.43$ (d. $1 \mathrm{H} . ~ J=8.3 \mathrm{H} \%$ ). $7.37(\mathrm{~d} .1 \mathrm{H} . J=1.9 \mathrm{H} \%) .7 .29(\mathrm{dd} .1 \mathrm{H} . J=1.9 .8 .3 \mathrm{H} \%) .3 .87-$ $3.84(\mathrm{~m} .2 \mathrm{H}) .3 .53-3.49(\mathrm{~m} .2 \mathrm{H}) .3 .34(\mathrm{q} .2 \mathrm{H} . J=6.9 \mathrm{H} \%$ ). $1.16(\mathrm{t} .3 \mathrm{H} . J=7.2 \mathrm{H} \%):{ }^{13} \mathrm{C}$ NMR ( $75 \mathrm{MH} \not . \mathrm{CDCl}_{3}$ ) $\delta$ 166.6. 153.3.137.5. 131.9. 130.2. 129.6. 127.6. 127.3. 61.9. 49.1. 42.4. 12.8.

1-(2,4-Dichlorobenzoyl)-3-methỵl-3-(2-hydroxyethyl)urca (3d). ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \approx . \mathrm{CDCl}_{3}$ ) $\delta 7.44(\mathrm{~d} .1 \mathrm{H} . J=8.3 \mathrm{H} \%$ ). $7.39(\mathrm{~d} . \mathrm{lH} . J=2.0 \mathrm{H} \delta) .7 .30(\mathrm{dd} .1 \mathrm{H} . J=2.0 .8 .3 \mathrm{H} /) \cdot 3.88-$ $3.85(\mathrm{~m} .2 \mathrm{H}) .3 .55-3.52(\mathrm{~m} .2 \mathrm{H}) .2 .98(\mathrm{~s} .3 \mathrm{H})$.

1-(2,4-Dichlorobenzoyl)-3-[(2-hyylroxy-1,1-dimethỵ)cthyl]urea (3c). ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \not . . \mathrm{CDCl}_{3}$ ) $\delta 9.19$ (bs. $1 \mathrm{H}) .8 .79(\mathrm{~s} .1 \mathrm{H}) .7 .57(\mathrm{~d} .1 \mathrm{H} . J=8.3 \mathrm{H} \mathrm{f}) .7 .48(\mathrm{~d} .1 \mathrm{H} . J=$ $1.9 \mathrm{~Hz}) .7 .36(\mathrm{dd}, 1 \mathrm{H} . J=1.9 .8 .3 \mathrm{~Hz}) .3 .61(\mathrm{~s} .2 \mathrm{H}) .1 .33(\mathrm{~s}$. $6 \mathrm{H}) .{ }^{1.3} \mathrm{C}$ NMR ( $75 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta$ 166.6. 153.1. 138.4 . 132.0. 131.4, 130.9. 130.6. 127.7, 70.2. 55.8. 24.5 .

1-(2,+-Dichlorobenzoyl)-3-(2-hydroxyethyl)urea (3f). ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta 8.64$ (bs, 1 H ). 7.62 (d. $1 \mathrm{H} . J=$ $8.4 \mathrm{~Hz}) .7 .48(\mathrm{~d} .1 \mathrm{H}, ~ J=2.0 \mathrm{~Hz}) .7 .36(\mathrm{dd}, 1 \mathrm{H}, ~ J=2.0 .8 .4$ Hz ). 3.82-3.78 (m. 2H), 3.55-3.49 (m. 2H): ${ }^{1.3} \mathrm{C}$ NMR (75 $\left.\mathrm{MHz} . \mathrm{CDCl}_{3}\right) \delta 166.2 .153 .8 .138 .5,1319.131 .1,130.6$. 127.8. 62.2. 42.8. 30.9

## General Procedure for Intramolecular Cyclization of 3.

To a stirred suspension of potassium $t$-butoxide ( 0.4 g .3 .6 $\mathrm{mmol})$ and aroylurea ( 1.5 mmol ) in tetrahydrofuran ( 20 mL ) under the nitrogen in an ice bath was added a solution of $p$ toluenesulfonyl chloride ( 0.34 g .1 .8 mmol ) in tetralydrofuran ( 5 mL ) dropwise using a syringe. The reaction mixture was stirred in an ice bath for 30 min . quenched with water ( 20 mL ), and extracted with ether ( $25 \mathrm{~mL} \times 2$ ). The crude product was purified by flash column chromatography.

1-Benzoyl-3-ethyl-2-imidazolidinone (+a). ${ }^{1} \mathrm{H}$ NMR (300
$\left.\mathrm{MH} \neq \mathrm{CDCl}_{3}\right) \delta 7.86-7.83(\mathrm{~m}, 2 \mathrm{H}) .7 .50-7.45(\mathrm{~m}, 1 \mathrm{H}) .7 .4(\mathrm{)}-$ $7.35(\mathrm{~m} .2 \mathrm{H}) .3 .92-3.89(\mathrm{~m}, 2 \mathrm{H}) .3 .48-3.44(\mathrm{~m} .2 \mathrm{H}) .3 .32(\mathrm{q}$. $2 \mathrm{H} . J=7.2 \mathrm{~Hz}$ ). 1.16 (t. $3 \mathrm{H} . J=7.2 \mathrm{H} \%$ ): HRMS calcd for $\mathrm{C}_{12} \mathrm{H}_{14} \mathrm{~N}_{2} \mathrm{O}_{2} 218.1055$, found 218.1045.

1-Benzoyl-4,+dimethyl-2-imidazolidinone (4b). $1 \mathrm{I} \%$ y icld: $R_{f}=0.5$ (acetonc/chloroform 3:10): mp 164-166 ${ }^{\circ} \mathrm{C}:{ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \not . . \mathrm{CDCl}_{3}$ ) $\delta 7.62-7.58(\mathrm{~m} .2 \mathrm{H}) .7 .47-7.4(\mathrm{~m}$. $1 \mathrm{H}) .7 .40-7.35(\mathrm{~m} .2 \mathrm{H}) .6 .00(\mathrm{bs} .1 \mathrm{H}) .3 .75(\mathrm{~s} .2 \mathrm{H}) .1 .29(\mathrm{~s}$. 6 H ): ${ }^{13} \mathrm{C}$ NMR ( $75 \mathrm{MH} \neq . \mathrm{CDCl}_{3}$ ) $\delta 170.5 .155 .0 .134 .6$. 131.2, 128.6. 127.4. 56.3, 51.2. 28.3: MS (EI) $\mathrm{m} / \mathrm{c} 219$ (M+1, 56). 218 (M, 95). $203(87) .190(66) .175(67) .113$ (93). 105 (100). 77 (93). The starting material 3 b was recoscred in $12 \%$ yicld. $R_{f}=0.4$ (acctone/chloroform $3: 10$ ).

4,4-Dimethyl-4,5-dihydro-N-benzoyl-2-oxazolamine (5b) $42 \%$ yicld: $R_{f}=0.4$ (ethyl acctate/n-hexanc $1: 1$ ): mp 79-81 ${ }^{\circ} \mathrm{C} .{ }^{\mathrm{H}} \mathrm{H} \operatorname{NMR}\left(300 \mathrm{MH} \% \mathrm{CDCl}_{3}\right) \delta 9.62$ (bs. IH). 8.25-8.23 (m. 2H). $7.49-7.38(\mathrm{~m} .3 \mathrm{H}) .4 .15(\mathrm{~s} .2 \mathrm{H}) .1 .42(\mathrm{~s} .6 \mathrm{H}){ }^{13} \mathrm{C}$ NMR ( $75 \mathrm{MH} \not . \mathrm{CDCl}_{3}$ ) $\delta 178.8$. 166,0. 136.7. 131.9. 129.4. 128.2.76.7. 58.4. 27.3: MS (EI) m/e 218 (M. 40). 217 (94). $141(96) .105(100) .77(88)$.

1-(2,4-Dichlorobenzoyl)-3-ethyl-2-imidazolidinone (tc) ${ }^{1} \mathrm{H}$ NMR (300) MȞ. $\mathrm{CDCl}_{3}$ ) $\delta 7.4(0-7.22(\mathrm{~m} .3 \mathrm{H})$. 4.07-4,01 (m. 2H). 3.55-3.53 (m. 2H). 3.31 (q. $2 \mathrm{H} . J=7.2 \mathrm{H} \%$ ). 1.174 (1. $3 \mathrm{H} . J=7.2 \mathrm{H} \%$ ): HRMS calcd for $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{Cl}_{2} \mathrm{~N}_{2} \mathrm{O}_{2} 286.0276$. found 286,0257 .

1-(2,4-Dichlorobenzoyl)-3-methyl-2-imidazolidinone (4d). ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MH} \not . \mathrm{CDCl}_{3}$ ) $\delta 7.4(0-7.21$ (m. 3 H ). $4.06-4.00$ (m. 2H). $3.55-3.50(\mathrm{~m} .2 \mathrm{H}) .2 .84$ (s. 3H): HRMS calcd for $\mathrm{C}_{11} \mathrm{H}_{10} \mathrm{Cl}_{2} \mathrm{~N}_{2} \mathrm{O}_{2} 272.01193$, found 272.01199 .

1-(2,4-Dichlorobenzoyl)-4,4-dimethỵl-2-imidazolidinone (4c). ${ }^{1} \mathrm{H} N \mathrm{NMR}\left(300 \mathrm{MH}, \mathrm{CDCl}_{3}\right) \delta 7.40-7.2 \mathrm{I}(\mathrm{m} .3 \mathrm{H}) .3 .84$ (s. 2H). 1.42 (s. 6 H ): HRMS calcd for $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{Cl}_{2} \mathrm{~N}_{2} \mathrm{O}_{2}$ 286,0276. Found 286,0286.

Acknowledgment. Financial support from the Brain Korca 21 program of the Ministry of Education is gratefully acknowledged. Spectroscopic analyses were performed in the Korea Basic Science Institute.

## References

1. (a) Lam, P. Y. S.: Jadhav, P. K.: Eyermani, C. J.: I Iodge. C. N.: Ru. Y.: Bacheler. L. T.: Meek. J. L.: Otto, M. J.: Rayner. M. M.: Wong. Y. N.: Chang, C-H.: Weher, P. C.: Tacksen, D. A. Shaper. T. R.: Frickson-Vitamen, S. Science 1994. 263, 380. (b) Wilkerson, W. W: Das, S: Cheatham. W. W. J. Aed. Chem. 1997, 10. 4079. (c) Patel, M: Bacheler, I.. T.: Rayner, M. M.: Cordova, B. C: Klabe, R. M.: Frickison-Vitanen, S: Seity, S. P. Bioorg. Med. Chem. Lett. 1998, 8. 823.
2. Heidempergher. F:: Pillan, A.: Pinciroli. V:: Vaghi. F: Arrigoni, C.: Bolis, G.: Caccia C.: Dho. L.: McArthur. R.: Varasi, M. J. Med. (hem. 1997, 10, 3369.
3. (a) (4R, $\bar{X})$ - 1.5 -Dimethyl-4-phenvl-2-midazolidinone: (Guillena. G.: Najera, C. Tetrahedrom: Asymmetry 1998. 9, 1125, and references cited therein. (h) (4))-4-(1-Methylethyl or phenymethyl)-1-phenyl-2-imidazolidinone: Taguehi, $T$, Shibuya, A: Sasaki, H.: Fndo, T.: Morikana, T.: Shiro, M. Tetrahedron: Asymmety 1994, 5, 1423, and references
cited thenein. (c) trans-4,5-Tetramethy lene-2-imidarolidinone: Davies, S. G.: Evans, G. B.: Mortlock, A. A. Tetrahedron: Aspmmety 1994, 5, 585. (d) Camphor-derived 2imidazolidinone: Palomo, C: Oiarbide, M.: Gonzalez, $A$. : Garcia, J. M.: Berree, F. Tetrahedon Letl. 1996, 37, 4565. (e) (4, 5 )-4-Carboxylate-2-imidazolidinone: Kubota, 11.: Kubo, A.: Takahashi, M.: Shimizu, R.: Da-te, T:: Okamura, K.: Nunami, K. J. Org. (hem. 1995, 60, 6776.
4. (a) Birkoter, I... Kuhlhau, H. P.: Ritter, A. Chem. Ber: 1960, 93, 2810. (b) Hay ward, R. J.: Meth-Cohn, O. I. (hem. Soc., Perkin Trans. I 1975, 212 . (c) Madaren, J. A. Aust. J. (hem. 1977, 30, 455. (d) Kim, J-M.: Wilson T. E..: Nomman, T. H.: Schuld, P. G. Tetrohedron Lett. 1996. 37. 5309.
5. Takeda, K : Ogura, H. Sinh. Comm. 1982, I2, 21 .
6. Ulrich, II: Tucker, B.: Richter. R. J. Ofg. Chem. 1978, f., 1544.
7. Kondo, K.: Yokoyama, S.: Miyoshi, N.: Murai, S.: Sonoda, N. Angew: Chem, Inl. Ed. Engl, 1979. IS, 692.
8. Davies, S. (i.: Mortlock, A. A. Tetrahedon 1993, f9, 4419.
9. Kim, I. II.: Lee, G.- J. J. Org. Chem. 1999, 6t, 2941.
10. Procedure for the preparation of 2,4-dichlorobenzoyl isocyanate See: Weikert, R. I.: Bingham, Jr, S.: Emanuel, M. $\Lambda .:$ Fraser-Smith, E. B.: Loughhead, D) (i.: Nelson, P? H.: Poulton, A. I. . J. Med. (hom. 1991, 34, 1630.
11. For a general discussion of the transier of activation, see: (a)Sobolow, S. B. Sun T. Cooper, B. A. Tetrahedron Lett. 1998. 39, 5685 . (b) Гissenstat, M. A.: Weaver, J. D. Tetrahedron Lett. 1995, 36, 2029.
12. Park. K. H.: Kurth. M. I. Tetrahedron Lett. 1999, 40 , 5841.
13. Katritzky, A. R.: Pleynet, D. P. M.: Yang, B. J. Org. Chem. 1997, 62, 4155.

[^0]:    ${ }^{n}$ Isolated sield by recrstallization. "Isolated sield by column chromatography: "The ratio of 2 -imidazolidimone 4 and 2 -ovazoline $\mathbf{5}$ was determined with ${ }^{1}$ I NMR data. "ne means mo cyclization reaction

